U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

Pleas note: we will be discontinuing the Global Markets Report after 28 February. Australian shares are set to open lower, ...

After two days of making his case to Senate committees, Robert F. Kennedy Jr.’s bid to lead federal health agencies still ...

The S&P 500 declined by 0.5% on Friday, Jan. 31, as investors digested the White House’s proposed tariffs on Canada, China, and Mexico.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in. The content of this article is provided for information ...

Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the stock market. When investing, your capital is at risk. The value of your ...

CRISPR Therapeutics and Vertex Pharmaceuticals ... the keys to navigating this complex but rewarding sector. 3 Source: Ben Fidler, "Three biotechs raise $700M in Rare burst of IPO activity ...

Real-time index price for Dow Jones Transportations Average (DOWT), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...

Vertex Pharmaceuticals ( VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic ...

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...